Omalizumab (Xolair): Anti‐Immunoglobulin E Treatment in Allergic Diseases
- 26 January 2007
- book chapter
- other
- Published by Wiley
Abstract
No abstract availableThis publication has 109 references indexed in Scilit:
- Efficacy of anti-IgE therapy in patients with atopic dermatitisJournal of the American Academy of Dermatology, 2006
- Omalizumab rapidly decreases nasal allergic response and FcεRI on basophilsJournal of Allergy and Clinical Immunology, 2004
- Immune Regulation by helminth parasites: cellular and molecular mechanismsNature Reviews Immunology, 2003
- Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2002
- OmalizumabDrugs, 2001
- A new role for CD23 in inflammationImmunology Today, 1996
- The high-affinity IgE receptor on eosinophils: From allergy to parasites or from parasites to allergy?Journal of Allergy and Clinical Immunology, 1994
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensThe New England Journal of Medicine, 1989